AOA executive director to step down, join new company

Article

The American Optometric Association announced this week that Executive Director Barry Barresi, OD, would be stepping down to join a newly formed company, Clinical Integration Partners.

St. Louis, MO-The American Optometric Association (AOA) announced this week that Barry Barresi, OD, AOA executive director and CEO of AOA Excel, would be stepping down to join Clinical Integration Partners, a newly formed company.

The Board of Directors of AOA Excel, a wholly owned business unit subsidiary of the AOA, plans to transfer the OcuHub assets to Clinical Integration Partners, as the project moves from the development phase to production. Clinical Integration Partners is seeking external capital funding to finalize the development and market release of OcuHub products.

Dr. Barresi has served as the AOA executive director since 2008. 

AOA has not announced plans for a successor. 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.